Press release – For immediate release– 5:45 pm CET
Half year liquidity contract statement
Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/31/2021:
- 20,093 shares
- € 231,217.23 in cash
During the second half of 2021, it has been traded a total of:
| BUY | 111,445 Shares | EUR 1,630,039.38 | 494 transactions |
| SELL | 108,704 Shares | EUR 1,619,230.25 | 397 transactions |
It is recalled that at the time of the half-yearly statement of 06/30/2021, the following resources were included in the liquidity account:
- 17,352 shares
- € 245,154.23 in cash
It is recalled that when the new liquidity contract was put in place on 05/04/2020, the following resources were made available:
- 4,404 shares
- € 173,829.64 in cash
The daily transaction table is provided in the appendix to this press release.
TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.